The [68Ga]Ga-DOTA-MGS5 scan revealed high tracer uptake in all FDG-avid lesions and identified additional abnormal foci, suggesting disease progression. The study suggests that CCK2R-targeting may be a new theranostic tool for ED-SCLC patients....
[99mTc]Tc-HYNIC-MGS5 and [68Ga]Ga-DOTA-MGS5: two novel imaging probes for cholecystokinin-2 receptor targetingdoi:10.1016/S0969-8051(19)30233-1M. KlinglerC. RanggerD. SummerC. DecristoforoE. Von GuggenbergNuclear Medicine and Biology
Conclusion: Besides confirming the safety of administration, within the phase I part of the prospective clinical trial, an acceptable effective whole-body dose, an overall favorable biodistribution, and the feasibility of cholecystokinin-2 receptor imaging could be shown for 68Ga-DOTA-MGS5.Elisabeth ...
The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using 68Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered to comply with the ...
68GaPETmedullary thyroid cancerPET/CT with the new 68Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (68Ga-DOTA-MGS5) was performed on patients with advanced medullary thyroid cancer (MTC) to evaluate cholecystokinin-2 receptor expres...